Explore the Agenda
7:45 am Morning Networking & Light Breakfast
8:20 am Chair’s Opening Remarks
Pinpointing Where Multimodal Approaches Deliver Value Today to Build the Evidence Base for Clinical Use Tomorrow
8:30 am Building a Multimodal Biomarker Profile: Combining Urine & Plasma ctDNA, RNA & Spatial Biology to Make Bladder-Preservation Decisions with Confidence
- Comparing personalized, fixed panel and methylation approaches head-to-head in the same patients to find the sensitivity needed for real clinical decisions
- Combining urine and plasma ctDNA with spatial and transcriptomic data to build a more complete patient profile
- Scaling deeper science into practical diagnostics, including where histopathology AI can reduce testing bottlenecks
9:00 am Session Reserved for Personalis
- Presentation details to be announced
9:30 am Panel Discussion: Harnessing Multimodal Technologies to Improve Patient Profiling for Increased Accuracy in Diagnostics
- Integrating protein, methylation and fragmentomic signal to resolve cases that genomic profiling alone leaves ambiguous
- Determining which analyte combinations improve accuracy enough to justify the added cost and complexity
- Embedding multi-omic workflows into patient selection and diagnostic paradigms
10:00 am Session Reserved for ClearNote Health
- Presentation details to be announced
10:30 am A Decade of Progress & the Gaps That Remain: What Real-World Data Tells Us About Liquid Biopsy Access & Clinician Adoption
- Sharing findings from a BLOODPAC study on how liquid biopsy is used in practice, mainly for treatment selection and increasingly for MRD, and where uptake is strongest
- Examining the barriers that remain, including clinician understanding of the tests and unequal access for underserved patient populations
- Considering what these lessons mean for the next stage, as the field moves further into MRD and multi-cancer early detection, and what drug developers and diagnostic companies can do to widen access
11:00 am Morning Break & Networking
Defining the Evidence Package & Regulatory Strategy to Enable MRD as an Endpoint in Trials
11:30 am Translating the Multiple Myeloma MRD Endpoint Precedent into Other Indications to Accelerate Clinical Trial Timelines: A Regulatory Perspective
- Unpacking how MRD came to be accepted as an early endpoint in myeloma and which parts of that evidence package transfer to solid tumours, so programs build on precedent rather than starting from zero
- Positioning MRD against pathological complete response in the neoadjuvant setting, where emerging breast and lung data show ctDNA reconciling the patients pCR calls wrong, to either replace or supplement the current readout
- Assessing composite endpoints, radiographic progression or ctDNA detection whichever comes first, as a route to de-risk a readout in indications where good standard of care pushes overall survival out to a decade
12:00 pm Panel Discussion: Translating the Multiple Myeloma Endpoint Precedent into Solid Tumor Programs to Shorten the Path to Regulatory Acceptance
- Unpacking what secured MRD acceptance in myeloma and which elements transfer to solid tumors
- Addressing the sensitivity and heterogeneity challenges that make the solid tumor case fundamentally harder
- Sequencing the evidence generation so indications build on each other rather than starting from zero
1:00 pm Lunch Break & Networking
Track A: Dose Optimization & Therapeutic Monitoring
Tracking Resistance Emergence & Target Expression Loss Across Successive Lines to Switch Therapy Before Radiographic Progression
2:00 pm Panel Discussion: Detecting & Tracking Acquired Resistance Mutations to Expedite Clinical Decision-Making
- Establishing monitoring intervals frequent enough to catch resistance emergence before clinical progression
- Distinguishing true resistance signal from clonal noise to avoid switching therapy on a false trigger
- Building switch criteria into protocols so molecular progression is an actionable endpoint, not an observation
2:30 pm Session to be Confirmed
Inquire about remaining partnership opportunities at sponsor@hansonwade.com
3:00 pm Tracking Response to KRAS G12C Inhibition with ctDNA: Liquid Biopsy Monitoring in Metastatic Colorectal Cancer
- Presenting how ctDNA was used to monitor treatment response in a sotorasib colorectal cancer study, and how changes in KRAS G12C levels in plasma relate to clinical outcomes
- Examining what ctDNA dynamics can add to imaging, including earlier read-outs of response and how monitoring could inform dose and treatment decisions
- Sharing practical lessons from running ctDNA monitoring in a clinical study, including assay choice, sampling schedules and interpreting results in a targeted therapy setting
3:30 pm Session to be Confirmed
Inquire about remaining partnership opportunities at sponsor@hansonwade.com
Track B: Patient Selection & Diagnostics
Generating Real-World & Health Economic Evidence to Unlock Reimbursement & Accelerate Adoption at Scale
2:00 pm From Great Test to Patient Access: Building the Validation, Reimbursement & Laboratory Pathways That Turn Blood-Based Tests into Standard Practice
- Designing tests for real-world access from the start, including platform choice, laboratory availability and payer requirements, so that strong science does not stall at the point of care
- Partnering with reference and clinical laboratories to bring tests in-house, close validation gaps and build lasting access rather than one-off workarounds
- Aligning evidence packages, reimbursement strategy and stakeholder expectations across pharma, diagnostics and laboratories so more patients can reach the right test
2:30 pm Session to be Confirmed
Inquire about remaining partnership opportunities at sponsor@hansonwade.com
3:00 pm Panel Discussion: Choosing the Right Diagnostic Partner for the Right Study to Deliver Regulatory-Grade Liquid Biopsy Data
- Matching assay type, sensitivity and turnaround to the study question, from patient selection and enrichment to response monitoring and MRD
- Evaluating vendors on analytical validation, quality systems and regulatory track record, so data stands up to agency scrutiny
- Structuring the sponsor and vendor relationship early, from contracting and sample logistics to bridging plans if the assay changes mid-program
3:30 pm Session to be Confirmed
Inquire about remaining partnership opportunities at sponsor@hansonwade.com
3:40 pm Afternoon Break & Networking
Applying Oncology’s Liquid Biopsy Playbook Beyond Oncology to Unlock Entirely New Therapeutic Markets
4:10 pm Diagnostics Landscape in Rare Diseases: Challenges, Solutions & Actions to Improve Patients’ Journey
- An overview of the rare disease landscape and key barriers to timely and accurate diagnosis
- Insights into development and adoption of diagnostics approaches, the influence on patient outcomes and healthcare delivery
- Fostering cross-sector collaboration to harmonize access and diagnostics standards to improve guidelines and patient care
4:40 pm Leveraging Blood-Based Biomarkers Beyond Oncology to Accelerate Clinical Trial Readouts
- Applying assay development and validation practice built in oncology to blood-based biomarkers in neurodegeneration and other non-oncology indications
- Reducing reliance on invasive and costly procedures such as imaging and tissue or CSF sampling, lowering screening cost and widening trial recruitment
- Adapting sampling and operational models to diseases that progress over years rather than weeks